Two drugs, isatuximab and lenalidomide, to treat multiple myeloma that doctors consider high-risk after autologous (your own cells) blood or marrow transplant (BMT)Print
18 - 70
Clinical Trial Goal
You may be able to join this trial if you:
- Are 18 - 70 years old
- Have multiple myeloma that doctors consider high-risk
- Have had or plan to have an autologous BMT
- Agree to have other standard tests done to see if you can be in the clinical trial
Lenalidomide is a drug that blocks growth of cancer cells.
You’ll get the following 2 - 6 months after autologous BMT:
- Isatuximab – Given as an intravenous (IV) infusion
- Lenalidomide - A pill that you take by mouth
You may continue treatment for up to 3 years. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 6 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial.
Muzzaffar Qazilbash, MD, (713) 745-3458, email@example.com
M D Anderson Cancer CenterRecruiting
Muzaffar Qazilbash, MD, 713-745-3458, firstname.lastname@example.org
lead: M.D. Anderson Cancer Center, collaborator: Sanofi
NCT05776979. First posted on Mar 20